Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03731533
Other study ID # 18-X-292
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date December 1, 2018
Est. completion date December 1, 2018

Study information

Verified date February 2020
Source Ohio University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, controlled comparison study that will evaluate the effectiveness of WellStart, a virtual intensive therapeutic lifestyle change program to control type 2 diabetes.


Description:

Purpose: To test the efficacy of WellStart Health program to to arrest and / or reverse type 2 diabetes.

Future comparative studies between programs programs are anticipated, utilizing this data to help identify the strengths and weaknesses of different programs, as well as identify subpopulations that might benefit from one program as opposed to another.

Data from this study will be shared via posters and papers among the lifestyle medicine community / publications to help contribute to better lifestyle interventions.

Pilot programs reported on the WellStart web page report reduction in hemoglobin A1c (HBA1c) and weight during the 12 week program.

The web site states:

Evidence for the Program:

The 12-week lifestyle medicine program provides online health coaching and education on 5 domains of wellbeing: whole food, plant-forward nutrition, movement, mindset and social support and resilience. The pilot programs have shown a mean weight reduction of 6.9 lbs in 85% of participants of the 12-week program. 85% of participants with prediabetes experienced a reduction in hemoglobin A1c, while 100% of those with diabetes had a mean hemoglobin A1c reduction of 1.1. WellStart has also helped 35% of participants on pharmacotherapy, eliminate medication (antihypertensives and metformin).

Studies have shown the ability of plant-based nutrition to reverse chronic disease including coronary artery disease. The BROAD study found a statistically significant reduction in BMI and cholesterol in those following a plant-based diet. Furthermore, Dean Ornish's research showed regression of coronary atherosclerosis after 5 years of a plant-based diet in addition to lifestyle changes and found that it reduced cardiac events by half. Caldwell Esselstyn's research on a whole food plant-based diet also demonstrated a significant reduction in major cardiac events in adherent patients.

Furthermore, a 2016 comprehensive literature review supports a plant-based diet as medical nutrition therapy for diabetes based on its ability to reduce fasting blood glucose, hemoglobin A1c, body mass index and reduce medication use.

The Diabetes Prevention Program (DPP), a lifestyle and diet intervention program, reduces the risk of diabetes by half in a population at risk. It has been successfully adapted to the online setting. WellStart is taking this concept a step further by providing participants with additional education and support to transition to plant-forward nutrition habits.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 1, 2018
Est. primary completion date December 1, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Established diagnosis of type 2 diabetes (T2DM)

- Between the ages of 18 and 65 years-old

- Own and willing to use a smart phone or computer, and have daily internet access

- Have an email account

- Have access to resources (finances and transportation) that allow for regular acquisition (at least once weekly) of groceries, including produce

- Access to resources that allow for food preparation at home (refrigeration, basic kitchen appliances and supplies)

- Willingness to attempt changes in food preparation and consumption, and physical activity.

-Scoring at least a 7/10 in both readiness for change and confidence of success; 1= not ready / no confidence; 10 = extremely ready / extremely confident of success -

Exclusion Criteria:

- Dementia

- Advanced renal disease (stage 4 or 5) with or without hemodialysis

- Congestive Heart Failure

- Taking warfarin

- Pregnancy or plans for pregnancy

- Current smoker of tobacco cigarettes

- Adults who have a physical limitation to prepare their own food or incorporate movement into their lifestyle (based on questionnaire answer)

- Brittle diabetes and/or history of hospitalization for high or low blood sugar

- Difficult-to-control hypertension and / or on 4 or more medications for high blood pressure.

- Does not speak or understand English

- Inability to use email or the Internet

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
WellStart
Five weekly automated text messages linked to an online article on health and wellness. Five weekly automated health coach motivational text message to smart phone. Optional back and forth text with their health coach is available. Daily Option to participate and post comments or questions in online discussion forum moderated by health coaches. Three group (up to 20 participants) health coach online visits (60 minutes). Two online group visits with a dietitian in groups of 10-12 participants. Three one-on-one online visits with a Physician Advisor to review progress, review any changes in medications by the primary medical provider (PCP), review biometrics and lab results, review safety guidelines and symptoms (30 minutes).

Locations

Country Name City State
United States Ohio University Athens Ohio

Sponsors (1)

Lead Sponsor Collaborator
Ohio University

Country where clinical trial is conducted

United States, 

References & Publications (4)

Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14;374(9702):1677-86. doi: 10.1016/S0140-6736(09)61457-4. Epub 2009 Oct 29. Erratum in: Lancet. 2009 Dec 19;374(9707):2054. — View Citation

Esselstyn CB Jr. Updating a 12-year experience with arrest and reversal therapy for coronary heart disease (an overdue requiem for palliative cardiology). Am J Cardiol. 1999 Aug 1;84(3):339-41, A8. — View Citation

Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998 Dec 16;280(23):2001-7. Erratum in: JAMA 1999 Apr 21;281(15):1380. — View Citation

Song M, Fung TT, Hu FB, Willett WC, Longo VD, Chan AT, Giovannucci EL. Association of Animal and Plant Protein Intake With All-Cause and Cause-Specific Mortality. JAMA Intern Med. 2016 Oct 1;176(10):1453-1463. doi: 10.1001/jamainternmed.2016.4182. Erratum in: JAMA Intern Med. 2016 Nov 1;176(11):1728. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Hemoglobin A1c glycosylated hemoglobin, measure of diabetes control over last 3 months 6 months
Primary Weight risk factor for diabetes 6 months
Secondary Short Form Health Survey - 36 Questions (SF-36) Survey of patient health status 6 months
Secondary Total cholesterol risk factor for cardiovascular disease, a comorbidity of diabetes 6 months
Secondary Low density lipoprotein cholesterol (calculated) risk factor for cardiovascular disease, a comorbidity of diabetes 6 months
Secondary High density lipoprotein cholesterol risk factor for cardiovascular disease, a comorbidity of diabetes 6 months
Secondary Triglycerides risk factor for cardiovascular disease, a comorbidity of diabetes 6 months
Secondary Systolic Blood Pressure risk factor for cardiovascular disease, a comorbidity of diabetes 6 months
Secondary Diastolic Blood Pressure risk factor for cardiovascular disease, a comorbidity of diabetes 6 months
Secondary Days per week of exercise Average days per week of exercise, self reported by patient 6 months
Secondary Minutes per day of exercise Average minutes per day of exercise, self reported by patient 6 months
See also
  Status Clinical Trial Phase
Completed NCT02771093 - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT02545842 - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL) Phase 4
Recruiting NCT03436212 - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump. N/A
Completed NCT03244800 - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. Phase 2
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Recruiting NCT06065540 - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Phase 3
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT04091373 - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide Phase 1
Completed NCT03296800 - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Phase 1
Recruiting NCT06212778 - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Completed NCT05979519 - Fresh Carts for Mom's to Improve Food Security and Glucose Management N/A
Recruiting NCT05579314 - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Terminated NCT03684642 - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Phase 3
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Completed NCT03644134 - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns N/A
Completed NCT05295160 - Fasting-Associated Immune-metabolic Remission of Diabetes N/A
Completed NCT02836873 - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Phase 3
Completed NCT02252224 - Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance